Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Intensity Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +3 vs. Q1 2026
- Shares held
- 1.17M
- +988.4K (+548.3%) vs. Q1 2026
- Total value
- $4.79M
- +$3.73M (+352.0%) vs. Q1 2026
- New holders
- 4
- 4 more added
- Sold out
- 1
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INTS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $4.79M |
| Q1 2026 | 14 | $1.06M |
| Q4 2025 | 35 | $1.63M |
| Q3 2025 | 26 | $721.2K |
| Q2 2025 | 27 | $606.6K |
| Q1 2025 | 21 | $5.10M |
| Q4 2024 | 20 | $4.79M |
| Q3 2024 | 20 | $6.65M |
| Q2 2024 | 23 | $8.23M |
| Q1 2024 | 18 | $8.54M |
| Q4 2023 | 17 | $4.39M |
| Q3 2023 | 10 | $1.19M |
| Q2 2023 | 2 | $170.2K |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Intensity Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 496,493 | $2.04M | 1.72% | +458,439+1,204.7% | Added |
| KMT Wealth Management, LLC | 496,493 | $2.04M | 1.72% | +496,493 | New |
| Sentinus, LLC | 26,723 | $109.6K | 0.01% | +3,429+14.7% | Added |
| Vanguard Capital Management LLC | 26,569 | $108.9K | 0.00% | +9,728+57.8% | Added |
| Sapient Capital LLC | 26,006 | $106.6K | 0.00% | 00.0% | Unchanged |
| Nano Cap New Millennium Growth Fund L P | 25,000 | $102.5K | 0.08% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 22,787 | $93.4K | 0.00% | −3,232−12.4% | Reduced |
| FNY Investment Advisers, LLC | 22,000 | $90.0K | 0.03% | +22,000 | New |
| Mesirow Financial Investment Management, Inc. | 14,118 | $57.9K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 9,121 | $37.4K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,984 | $8.13K | 0.00% | +1,917+2,861.2% | Added |
| GWM Advisors LLC | 1,148 | $4.71K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 200 | $820 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 42 | $172 | 0.00% | +42 | New |
| Morgan Stanley | 20 | $82 | 0.00% | 00.0% | Unchanged |
| Caitong International Asset Management Co., Ltd | 6 | $25 | 0.00% | +6 | New |
| UBS Group AG | 1 | $4 | 0.00% | −191−99.5% | Reduced |
| Wells Fargo & Company | 0 | $0 | 0.00% | −200−100.0% | Sold out |